May 25, 2016
Ono Pharmaceutical’s etelcalcetide met the primary endpoint in a PIII clinical study in Japan in hemodialysis patients with secondary hyperparathyroidism, a complication of chronic renal failure. The drug is pending approval for this indication in the country. The results of...read more